Sonrotoclax with steroid and other drugs for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has relapsed (come back) or is progressing after prior treatment, or is not responding as expected.
- Your myeloma has measurable signs: one of the lab patterns must be high enough (M-spike, urine protein M-spike, or specific blood “free light chain” levels with an abnormal ratio).
- Your cancer must have the t(11;14) change in the cells (confirmed by a specific lab test called FISH from a bone marrow sample).
- You can do daily activities fairly normally (ECOG 0 to 2).
- Your blood counts and organ blood tests are high/normal enough before starting (for example, hemoglobin, platelets, and neutrophils, plus liver and bilirubin levels).
- You do not have certain other blood cancers or related conditions like active plasma cell leukemia, Waldenström macroglobulinemia, amyloidosis, or POEMS, and you’re not on continuous oxygen for lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
This trial tests a new combination of drugs for people with multiple myeloma that has come back after previous treatment. The goal is to see if adding belantamab mafodotin to standard drugs can help control the disease better.
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
This trial tests a new oral drug, surzetoclax, given alone or with other myeloma treatments, in adults whose myeloma has come back or stopped responding to treatment. It may help slow the disease and improve symptoms.
This study tests a new combination of drugs for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if the combination helps control the disease.
This trial is testing a combination of three drugs (carfilzomib, cyclophosphamide, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to previous treatments, especially if they've already had lenalidomide. The goal is to see if this combination can help control the cancer.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.